Gout
Drug research and approvals for gout: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 38 studies of gout are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, FDA has 2 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 38
- Trials authorized in Canada: 1
- FDA orphan approvals: 2
- EU medicines: 1
Recruiting Now
Newest start dates first, of 38 recruiting on ClinicalTrials.gov ↗- Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With GoutNCT06887452 · Not applicable · VA Office of Research and Development · starts Oct 1, 2026
- SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) TrialNCT06674109 · Phase 4 · Massachusetts General Hospital · starts Jul 1, 2026
- A Study of IN026 in Participants With Refractory GoutNCT07587684 · Phase 1 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · starts Jun 12, 2026
- Tart Cherry Citrate Effervescent Tablet for Urate-Lowering Therapy in Participants With Asymptomatic HyperuricemiaNCT07613138 · Not applicable · Beijing Zhecheng Biotechnology Co., Ltd. · starts Jun 4, 2026
- Digital Care for Holistic Health in Older Adults With Diabetes and MultimorbidityNCT07310849 · Not applicable · Chang Gung University of Science and Technology · starts May 12, 2026
- A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout ParticipantsNCT07535034 · Phase 2 · Crystalys Therapeutics · starts May 8, 2026
- The Remote Monitoring of Gout Feasibility Study in Primary CareNCT07490522 · Not applicable · Diakonhjemmet Hospital · starts Apr 1, 2026
- The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and…NCT07362355 · Phase 2 · Jiangsu HengRui Medicine Co., Ltd. · starts Feb 9, 2026
- A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase…NCT07388498 · Phase 3 · Amgen · starts Feb 9, 2026
- ACUTE-GO is a Study Testing the Effectiveness and Safety of Two Doses of Purified Cortrophin Gel in Patients With Acute…NCT07938164 · Phase 4 · ANI Pharmaceuticals · starts Jan 28, 2026
Drug Pipeline
12 approved, 8 in phase 3, 14 in phase 2, 2 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Allopurinol, Febuxostat, Colchicine, Pegloticase, Lesinurad, Naproxen, Rasburicase, Cinchophen, Benzbromarone, Sulfinpyrazone, Probenecid, Tisopurine
- Canakinumab
- Phase 3 Interleukin-1 beta inhibitor
- Rilonacept
- Phase 3 Interleukin-1 beta inhibitor
- Pegadricase
- Phase 3 Uric acid oxidative enzyme
- SHR-4640
- Phase 3 Solute carrier family 22 member 12 inhibitor
- Celecoxib
- Phase 3 Cyclooxygenase-2 inhibitor
- Betamethasone dipropionate
- Phase 3 Glucocorticoid receptor agonist
- Lansoprazole
- Phase 3 Potassium-transporting ATPase inhibitor
- Dotinurad
- Phase 3 Solute carrier family 22 member 12 inhibitor
- Verinurad
- Phase 2 Solute carrier family 22 member 12 inhibitor
- Ulodesine
- Phase 2 Purine nucleoside phosphorylase inhibitor
- Anakinra
- Phase 2 Interleukin-1 receptor antagonist
- Arhalofenate
- Phase 2 Peroxisome proliferator-activated receptor gamma modulator
- Diacerein
- Phase 2 Unknown
- Azathioprine
- Phase 2 Amidophosphoribosyltransferase inhibitor
- Diclofenac
- Phase 2 Cyclooxygenase inhibitor
- Mycophenolate mofetil
- Phase 2 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Denosumab
- Phase 2 Tumor necrosis factor ligand superfamily member 11 inhibitor
- Methylprednisolone acetate
- Phase 2 Glucocorticoid receptor agonist
- Dexamethasone
- Phase 2 Glucocorticoid receptor agonist
- Apremilast
- Phase 2 Phosphodiesterase 4 inhibitor
- Bucillamine
- Phase 2 Antioxidant
- Isobromindione
- Phase 2
- Methotrexate
- Phase 1 Dihydrofolate reductase inhibitor
- Rituximab
- Phase 1 B-lymphocyte antigen CD20 binding agent
How Its Trials Ended
190 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 59 whose ending is known, 73% met their primary endpoint, 5% missed it and 22% stopped early.
- Completed, result not reported7439%
- Met its primary endpoint4323%
- Ongoing3619%
- Status unknown2111%
- Stopped: other or unclear53%
- Missed its primary endpoint32%
- Stopped: lack of efficacy32%
- Stopped: enrollment or feasibility21%
- Stopped: sponsor or business decision21%
- Stopped: funding11%
Trials Authorized in Canada
Newest first; search them all in Canada trials| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Mar 3, 2014 | A randomized, double-blind, active and placebo-controlled study to evaluate the efficacy and safety of arhalofenate for preventing flares and reducing serum…Arhalofenate (MBX-102) | Cymabay Therapeutics Inc | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Jul 7, 2022 | KrystexxaTreatment of chronic gout in adult patients refractory to conventional therapy | Horizon Therapeutics Ireland DAC | Approved |
| Sep 14, 2010 | KrystexxaTreatment of chronic gout in adult patients refractory to conventional treatment | Horizon Therapeutics Ireland DAC | Approved |
| Jun 6, 2005 | Polyethylene glycol-modified uricaseTreatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated | Swedish Orphan Biovitrum AB | Designated |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Apr 21, 2008 | AdenuricFebuxostat | Menarini International Operations Luxembourg S.A. (MIOL) | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA